2023 2H Business Update
In 2023, Tasso achieved remarkable growth driven by our unwavering focus on expanding access to care for more patients by offering convenient diagnostic healthcare options. Our patient-centric blood collection solutions have proven to be a valuable addition to the pharmaceutical and healthcare industry. Several new engagements forged in the second half of 2023 support our continued growth and ability to offer more complete solutions to the industry.
As we head toward 2024, Tasso aims to remain at the forefront of a pivotal shift toward patient-centric, remote blood sample collection and decentralized clinical trials. We are excited to continue to expand and increase our capabilities as a new gateway to healthcare.
Tasso is dedicated to improving the patient experience with easily accessible diagnostics that help clinicians make better informed decisions about patient health. We deeply value every collaboration, whether these are commercial, community-centric or clinical in nature. Each one is critical to our growth and has helped Tasso expand our reach this year.
In 2024, we hope to continue these collaborations and find ways to offer novel, personalized diagnostic solutions to the marketplace.
2023 2H Business Highlights:
Expanding our Commercial Footprint
At Tasso, our mission is to improve patient experiences and health with expanded access to care. Growing our footprint across more regions and industries is critical to our success. Our recent certifications and new business relationships demonstrate our commitment to growth.
We received CE Mark certification for the Tasso+® device, allowing us to offer patient-centric, high-volume blood collection solutions in the European Union (EU) market, including 28 member states, plus Iceland, Norway and Lichtenstein. The CE Mark designation ensures a product has met all European Commission safety, health and environmental protection requirements. With the CE Mark certification, Tasso+ now has achieved full clearance in the U.S. and the EU to sell devices, making it the first device of its kind to do so.
We announced the successful completion of the System and Organization Controls (SOC) 2 Type 2 audit, providing compliance certification for our platform. The SOC 2 Type 2 audit is conducted by independent auditors to determine whether a company is maintaining a high standard for handling sensitive client data through its operations, controls, and processes. This achievement demonstrates our ability to securely manage client data and highlights our company’s commitment to meeting the highest industry standards.
We announced a new engagement with Randox Health, which provides at-home and in-clinic health tests as part of Randox – the largest healthcare diagnostics company in the United Kingdom and Ireland – to offer at-home healthcare diagnostic testing powered by our innovative blood collection technology. Randox Health is the first major laboratory in the United Kingdom to validate the Tasso devices and offer them to consumers for at-home health and wellness diagnostic testing for individuals to make better informed decisions about their health.
Our relationship with ZOE, a personalized nutrition company headquartered in the UK, will expand access to the Tasso+ blood collection device as part of a personalized nutrition program from the world’s largest nutrition-science study. By offering the Tasso+ device in its test kits, ZOE consumers will have access to virtually pain-free, efficient and simple blood sample collection – allowing them to incorporate data from certain biomarkers into their individualized nutrition program.
Serving the Community Through Collaboration
Making testing accessible and convenient is key to supporting underserved populations. Tasso is proud to make life-changing care and research possible through our technology.
Renegade.bio, an LGBTQ-owned public benefit corporation, announced that they will include Tasso devices as part of Renegade.bio’s at-home sexually transmitted infections (STI) testing kits. By offering Tasso devices, which allow convenient, virtually painless blood collection, Renegade.bio aims to increase access to STI testing, improve the patient experience, and reduce HIV and STI-related health disparities and inequities.
Our technology contributed to the research success of the Million Veterans Program, a national research program looking at how genes, lifestyle, military experiences, and exposures affect health and wellness in Veterans. Since its launch in 2011, the program has accumulated 1 million veterans and has become the largest research effort at Veterans Affairs to improve health care for veterans.
Forging New Laboratory and Clinical Relationships
Tasso is synonymous with gold standard clinical quality. We choose to work with laboratories that share our passion for producing the best quality samples and data. These exciting new collaborations will expand what is possible using remote blood samples.
Our new partnership with Quest Diagnostics, the leading provider of diagnostic information services, allows patients and healthcare providers access to Tasso’s convenient, easy-to-use and virtually painless blood collection devices. Through a series of collaborations, the partnership brings together Tasso’s innovative clinical-grade blood sample collection devices and end-to-end collection and analysis solutions with Quest’s world-class lab processing capabilities.
Biodesix, a leading diagnostic solutions company with a focus in lung disease, is working with Tasso to create a new method for patients to collect blood specimens for Nodify Lung Nodule Risk Assessment testing using Tasso+.
Reaching New Milestones with Pharma
Tasso works closely with leaders across pharma to envision and develop the next generation of decentralized clinical trial solutions. We celebrated several milestones this year marking the adoption of Tasso technology for trials worldwide.
Tasso is now working with 13 of the 15 largest pharmaceutical companies.
Tasso devices have been used successfully in Phase I, Phase II, and Phase III clinical trials.
New publications from Pfizer and Genentech highlighted the applications of Tasso’s devices for decentralized clinical trials.